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Abstract
Purpose Breast cancer is the leading cause of cancer death in females. Histone modifications have been shown to have an 
influence on the gene expression. This study focusses on the histone modifications H3K9ac and H3K4me3 in breast cancer 
and their impact on survival
Methods H3K4me3 and H3K9ac expression was immunohistochemically examined in 235 tissue samples.
Results Positive estrogen receptor status was correlated with a higher IRS of the nuclear (p = 0.033), and of the cytoplasmic 
H3K4me3 staining (p = 0.009). H3K9ac intensity was associated to the Her2 status (p = 0.045) and to poor prognosis in 
cells with positive Ki67 status (p = 0.013). A high intensity of nuclear H3K4me3 staining was found to be correlated with a 
lower 10-year-survival (p = 0.026) and with lower breast cancer-specific survival (p = 0.004). High percentage score (> 190) 
of H3K9ac expression was correlated to worse breast cancer-specific survival (p = 0.005). Shorter progression-free survival 
was found in patients with nuclear (p = 0.013) and cytoplasmic H3K4me3expression (p = 0.024) and H3K9ac expression 
(p = 0.023).
Conclusion This analysis provides new evidence of histone modifications in breast cancer. High H3K4me3 and H3K9ac 
expression was correlated with survival rates. Further investigation of histone modifications in breast cancer could lead to 
a more profound understanding of the molecular mechanisms of cancer development and could result in new therapeutic 
strategies.
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Abbreviations
H3K4me3  Histone H3 trimethyl K4
H3K4ac  Histone H3 acetyl K9
DCIS  Ductal carcinoma in situ
HDAC  Histone deacetylase inhibitor
LCIS  Lobular carcinoma in situ
OS  Overall survival
DSS  Disease-specific survival
PFS  Recurrence-free survival
Local PFS  Period of time until a local recurrence was 
diagnosed
DDFS  Period of time until metastasis is diagnosed
Introduction
Breast cancer is the most frequently diagnosed cancer and 
the leading cause of cancer death in females worldwide, 
accounting for 25% (1.7 million) of the total new cancer 
cases and 15% (521.900) of the total cancer-related deaths in 
2012 (Torre et al. 2017). Breast cancer remains a significant 
threat to women all over the world, even though the breast 
cancer death rates have decreased by 40% between 1975 and 
2017 (DeSantis et al. 2019).
Gene expression profiling has had an important impact 
on the understanding of breast cancer (Bell et al. 2017). For 
example, the analysis of certain biomarkers such as hormone 
receptor status, Her2 status and expression of Ki67 has led 
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to the characterization of molecular subtypes of breast can-
cer that have shown significant differences in terms of their 
incidence, risk factors, prognosis and sensitivity to treatment 
(Prat et al. 2015).
Epigenetic alterations, such as DNA methylation and 
posttranslational modification of histones have been shown 
to have a considerable influence on the gene expression (Wu 
et al. 2015). Histones are the central component of the nucle-
osomes’ subunit. They form an octamer containing the four 
core histone proteins (H3, H4, H2A, H2B) around which is 
wrapped a 147-base-pair segment of the DNA (Audia and 
Campbell 2016). The histones’ N-terminal tails extend from 
the double-strand DNA and are subject to posttranslational 
modifications, which include acetylation, methylation, phos-
phorylation, ADP-ribosylation, glycosylation, sumoylation 
and ubiquitylation (Zhang et al. 2016). Histone acetylation 
is primarily associated with gene activation, whereas meth-
ylation, depending on its position and state, can either be 
associated with repression or activation (Wang et al. 2008).
Previous studies have analyzed the impact of specific 
posttranslational modifications on the gene expression (Law-
rence et al. 2016). For example, H3K4 methylation has been 
intensely studied regarding the enzymes and molecular fac-
tors required for methylation (Shilatifard 2008). An asso-
ciation between high H3K4me3 expression and poor prog-
nosis was found in patients with hepatocellular carcinoma 
and cervical carcinoma (Beyer et al. 2017; He et al. 2012). 
In cervical cancer, the same observation has been made for 
H3K9ac (Beyer et al. 2017).
As a thorough investigation regarding the influence of his-
tone modifications on the prognosis of breast cancer patients 
was lacking, an expression analysis of histone H3 trimethyl 
K4 (H3K4me3) and histone H3 acetyl K9 (H3K9ac) was 
performed in this study. 235 tissue samples were examined 




A panel of 235 tissue samples from patients who underwent 
surgery at the Ludwig-Maximilians-University, Munich 
between 1998 and 2000 due to malignant breast cancer was 
used. The mean patients’ age was 58.2 ± 13.3 years. 43.8% of 
the breast cancer cases were classified as Luminal A, 31.5% 
as Luminal B and Her2 negative, 6.8% as Luminal B and 
Her2 positive, 3.0% as Her2 positive and hormone receptor 
negative; 13.2% were triple negative carcinomas. 65.1% of 
the patients were diagnosed with a tumor size smaller than 
2 cm, 28.1% had a tumor between 2 and 5 cm. At least one 
regional lymph node was affected in 39.6% of the cases. 
7.2% were ranked as low grade, 36.6% as intermediate grade 
and 22.6% as high-grade tumors. In 33.6%, the grading-
classification was missing. DCIS and LCIS fractions were 
observed in 51.1% of the cases. For more patients’ charac-
teristics’ see Table 1.
The endpoints were defined as following: OS = overall 
survival, period of time from the date of surgery until the 
date of death or date of last follow-up; DSS = disease-spe-
cific survival, period of time from the date of surgery until 
the breast cancer-dependent death; PFS = progression-free 
survival, period of time until local recurrence or metasta-
sis were diagnosed; local PFS = period of time until a local 
recurrence was diagnosed; DDFS = distant disease-free sur-
vival, period of time until metastasis is diagnosed.
Ethics approval
The tissue samples were originally collected for histopatho-
logical diagnostics. They were no longer used for clinical 
tests when being selected for this study. Patient data was 
anonymized and the authors were blinded for the patients’ 
information as well as for survival time during the analysis. 
The study was approved by the local ethics committee of the 
Ludwig-Maximilians-University of Munich (Reference No. 
048-08; 2008) and was performed according to the Declara-
tion of Helsinki.
Immunohistochemistry
The formalin-fixated and paraffin-embedded tissues were 
first dewaxed in xylol. After rinsing the tissue in 100% 
ethanol, the endogenous peroxidase was inactivated in 
3%  H2O2 in methanol and the samples were rehydrated in 
a descending alcohol series. To unmask the antigen, the 
samples were heated up to 100 °C in a dilution with citrate 
buffer for 5 min. After washing the samples in distilled 
water and PBS-buffer, a blocking solution was applied 
to prevent unspecific staining due to binding of the anti-
bodies to electrostatic charges in the tissue. The samples 
were then incubated at 4 °C with the primary antibody 
for 16 h (see Table 2). A Purified solution of Antibodies 
bought from the producer was used. The specificity of the 
antibodies was already tested by CHiP Sequence by other 
authors and the producer (Abcam; Lima-Fernandes et al. 
2019). After intensifying the staining with a Post-Block 
Solution, the HRP polymer was applied. The excess HRP 
Polymer was removed and the binding of the antibody was 
made visible through an enzymatic reaction using diam-
inobenzidine (DAB). A counterstaining was performed in 
haemalaun (2 min), followed by dehydration in an ascend-
ing alcohol series and covering of the samples. Placenta 
tissues were used as positive and negative controls for each 
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staining of H3K4me3 and H3K9ac (Fig. 1b and d). The 
results of the staining were analyzed using two different 
scores. The immunoreactive score (IRS-Score) multi-
plies the intensity of the staining (0 = not stained, 1 = low 
intensity, 2 = moderate intensity, 3 = high intensity) with 
the percentage of stained tumor cells (0 = 0%, 1 = 1–10%, 
2 = 11–50%, 3 = 51–80%, 4 =  > 80%). The result is a value 
between 0 and 12. The %Score multiplies the staining 
intensity (0 = not stained, 1 = low intensity, 2 = moderate 
intensity, 3 = high intensity) with the percentage of stained 
tumor cells, allowing a finer differentiation of the samples 
regarding the percentage of stained cells (range: 0–300%).
Statistics
IBM SPSS Statistics version 25 (Armonk, NY, USA) was 
used. Spearman’s-rank correlation coefficient was employed 
to calculate bivariate correlations. To compare independ-
ent groups non-parametric tests (NPAR: Kruskal–Wal-
lis test, Mann–Whitney U test) were used. Survival times 
were shown by Kaplan–Meier estimates and calculated 
by log-rank-test, thresholds were defined experimentally. 
The p value of the tests had to be < 0.05 to be statistically 
significant.
Results
H3K4me3 staining in breast cancer
71.4% of the samples showed a nuclear staining with a 
median immunoreactive score of 2 and a median percent-
age score of 40 (Fig. 1a). 26.0% displayed no nuclear stain-
ing. 20.4% of the samples had low staining (IRS ≤ 2), while 
44.3% showed an enhanced staining (IRS > 2) and, therefore, 
high expression of H3K4me3 in the nucleus. 9.3% of the 
samples could not be analyzed. An additional staining of 
the cytoplasm was found in 35.1% of the samples. Placenta 
tissue was used as positive control (Fig. 1b).
The correlations between the H3K4me3 expression and 
several important clinical parameters, such as the estrogen 
receptor status and the Her2 status, as well as the H3K9ac 
Fig. 1  H3K4me3 and H3K9ac staining in BC and placenta. a H3K4me3 staining in BC; b positive control (placenta) H3K4me3; c H3K9ac 
staining in BC; d positive control (placenta) H3K9ac
2020 Journal of Cancer Research and Clinical Oncology (2020) 146:2017–2027
1 3
expression, were analyzed by applying Spearman’s rank cor-
relation coefficient (see Table 3).
An association between H3K4me3 and the tumor cells’ 
estrogen receptor status was observed: Positive estrogen 
receptor status was correlated with a higher IRS of the 
nuclear staining (p = 0.033, Rho = 0.147; Fig. 2a–c): the 
median of nuclear H3K4me3 expression in estrogen posi-
tive cells was 3, compared to 2 in estrogen negative cells. 
ER expression was also associated to a higher intensity 
(p = 0.006, Rho = 0.186) and IRS (p = 0.009, Rho = 0.179) of 
the cytoplasmic staining (Fig. 2d–f; see Table 3). Although 
the difference is significant, the correlation is weak and can-
not be seen in the boxplot.
No significant correlation was found regarding the his-
tological subtype, T-stage, N-stage, grading, Ki67 status, 
PR, Her2 status and clinical subtype (Luminal A, Luminal 
B, basal like triple negative Her2 positive typ luminal, Her2 
positive typ non-luminal) (see Table 3).
A correlation between the H3K9ac staining and the 
nuclear H3K4me3 staining (p = 0.000; Rho = 0.633), as 
well as the cytoplasmic H3K4me3 staining (p = 0.000; 
Rho = 0.448) was found, showing that intense H3K4me3 
staining is associated with increased H3K9ac expression 
(see Table 4).
H3K9ac staining in breast cancer
A total of 72.4% of the samples showed a nuclear staining 
with a median IRS of 3 and a median percentage score of 
60 (Fig. 1c). Unlike the H3K4me3 staining, no additional 
staining of the cytoplasm was found. 28.5% of the samples 
had low staining (IRS ≤ 3), while 40.9% showed an enhanced 
staining (IRS > 3) and 26.4% did not show any staining. 
4.2% of the samples could not be analyzed. Placenta tissue 
was used as positive control (Fig. 1d).
As mentioned above, a correlation between the H3K4me3 
staining and the H3K9ac staining was found (see Table 4). 
Furthermore, a high H3K9ac staining intensity was shown 
Table 1  Patients’ characteristics
N %
Age (median) 58.2 –
Histopathology
 Luminal A 103 43.8
 Luminal B
  Luminal B Her2 negative 74 31.5
  Luminal B Her2 positive 16 6.8
  Her2 positive, HR negative 7 3.0
  Triple negative 31 13.2
  NA’s 4 1.7
 < 2 cm 153 65.1
 2–5 cm 66 28.1
 > 5 cm 1 0.4
 T4 5 2.1
 NA’s 10 4.3
 Grade 1 17 7.2
 Grade 2 86 36.6







 DCIS/LCIS positive 120 51.1




 At least one 64 27.2
 Not available 32 13.6
Survival (over 14.7 years)
 Right censured 149 63.4
 Died 78 33.2
 Not available 8 3.4
Table 2  Staining procedure
a Anti histone H3 tri methyl K4, rabbit IgG polyclonal, concentration: 0.2 mg/ml, company: Abcam, order number: ab8580
b Anti histone H3 acetyl K9, rabbit IgG monoclonal, clone Y28, concentration: 0.059 mg/ml, company: Abcam, order number: ab32129
c ZytoChem Plus HRP Polymer Kit (Mouse/Rabbit) 3 × 100, company: Zytomed Systems (Berlin, Germany) Nr. POLHRP-100
d Dulbecco’s phosphate buffered saline
e Lipuid DAB + substrate chromogen system 1 mg/ml, DAKO
Histone H3 tri methyl  K4a Histone H3 acetyl  K9b
Blocking  solutionc: 5 min Blocking  solutionc: 5 min
Primary  antibodya: 1:100 in  PBSd, incubation: 16 h, 4 °C Primary  antibodyb: 1:200 in  PBSd, incubation: 16 h, 4 °C
PostBlockc: 20 min PostBlockc: 20 min
HRP  Polymerc: 30 min HRP  Polymerc: 30 min
Chromogen:  DABe (1 min) Chromogen  DABe (30 s)
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to be correlated with a positive Her2 status of the tumor cells 
(p = 0.045, ρ = 0.134; Table 3; Fig. 3), but the correlation 
was weak.
The categorization of the molecular subtype is an impor-
tant part of the breast cancer diagnosis, as it influences the 
patient’s treatment and allows to give an approximate prog-
nosis. To further refine the prognosis in specific subcatego-
ries, more markers are useful. The expression of H3K9ac 
was identified as a potential marker. Regarding the Ki67 
status, H3K9ac expression was found not to be directly asso-
ciated to Ki67 expression. But in samples with positive Ki67 
status (defined as more than 14% of the tumor cells being 
positive for Ki67), H3K9ac expression was associated with 
poor prognosis (p = 0.013; Fig. 4).
No significant correlation was found regarding the 
T-stage, N-stage, estrogen receptor status, grading, the PR 
and the clinical subtype.
Role of H3K4me3 and H3K9ac on survival
A high intensity of nuclear H3K4me3 staining (intensity = 3) 
was found to be correlated with a lower 10-year survival in 
breast cancer patients (p = 0.026; Fig. 5a). Taking into con-
sideration only the patients that died due to breast cancer, we 
found out, that patients had to have a %Score > 110 to show a 
significantly better breast cancer-specific survival (p = 0.004; 
Fig. 5b). The cytoplasmic expression of H3K4me3 had no 
visible effect on the survival of the patients.
The examination of the role of H3K9ac showed no sig-
nificant effect on the overall survival. Regarding the breast 
cancer-specific survival, patients with a high %Score had a 
worse prognosis (p = 0.005; Fig. 5c). The threshold needed 
for significant results was %Score > 190.
Role of H3K4me3 and H3K9ac on progression‑free 
survival
In addition to the impact on the patient’s general survival, 
nuclear H3K4me3 expression was also correlated with the 
progression-0free survival. The distant disease-free survival, 
as well as the local disease-free survival, was decreased in 
patients with %Score > 150 (p = 0.005 and p = 0.049; Fig. 6a 
and b). Combining these two parameters, a significantly 
shorter general progression-free survival was found in these 
patients (p = 0.017; Fig. 6c).
While the cytoplasmic expression of H3K4me3 seemed 
to have no impact on the overall survival, it was correlated 
with a shorter progression-free survival in patients with a 
%Score ≥ 60 (p = 0.034; Fig. 6d). These patients also showed 
a shorter distant disease-free survival (p = 0.024; Fig. 6e). 
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A shorter recurrence-free survival was also found 
in patients with a high nuclear expression of H3K9ac 
(%Score > 225, p = 0.023; Fig. 6f).
Discussion
This study showed that specific histone modifications are 
important in breast cancer patients. H3K4me3 expression 
was correlated with positive estrogen receptor status, while 
H3K9ac staining was correlated with positive Her2 receptor 
status. Although results were highly significant, the correla-
tions themselves were weak.
High H3K4me3 and H3K9ac expression were correlated 
with shorter breast cancer-specific survival as well as shorter 
progression-free survival. Overall survival was decreased in 
patients with high nuclear H3K4me3 staining.
Fig. 2  Correlation of H3K4me3 Nuc and Cyt and ER. a Boxplot: 
Difference of H3K4me3 Nuc expression in regard to ER status; b 
H3K4me3Nuc staining (IRS 9) and ER positive; c H3K4me3Nuc 
expression (IRS 2) and ER negative; d Boxplot: H3K4me3 Cyt 
expression in regard to ER status; e H3K4me3Cyt staining (IRS 8) 
and ER positive; f H3K4me3Cyt expression (IRS 3) and ER negative
Table 4  Correlation of H3K4me3 and H3K9ac
H3K4me3 Nuc H3K4me3 Cyt
p ρ p ρ
H3K9ac 0.000 0.633 0.000 0.448
Fig. 3  Correlation of H3K9ac and Her2neu. a Boxplot: correlation of Her2neuexpression and H3K9ac; b H3K9ac staining (IRS 8) and Her2neu 
positive; c H3K9acexpression (IRS 3) and Her2 negative
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trimethylated) (Kimura 2013; Lee et al. 1993; Vakoc et al. 
2006). In this study, we analyzed the impact of H3K4me3 
and H3K9ac on the survival of breast cancer patients, as 
these modifications have been described to be associated 
with active chromatin (Ruthenburg et al. 2007).
H3K4 methylation is a modification occurring at the 
fourth lysine residue from the N-terminus of Histone H3. It 
can be mono-, di- and trimethylated, which adds to the com-
plexity of the analysis of its impact on the genome (Taka-
hashi and Shilatifard 2010). H3K4me3 is generally associ-
ated with transcriptional activation and has been proposed 
as a predictive factor of poor prognosis in several types of 
cancer, such as liver and cervical cancer (Li et al. 2018). 
Poorer prognosis has also been described for patients with 
cervical cancer with a high expression of H3K9ac (Beyer 
et al. 2017).
By its neutralizing acetyl-group, H3K9ac leads to a de-
condensation of the DNA structures and to an activation of 
transcription (Lee et al. 1993). The effect of an acetylated H3 
at position 9 depends on the tumor entity: high H3K9ac lev-
els seem to be associated with a poor prognosis in cervical 
cancer (Beyer et al. 2017), while patients with glioma have 
better prognosis with high H3K9ac levels (Liu et al. 2010).
There are much more histone modifications beside 
H3K4me3 and H3K9ac, which are associated to activa-
tion of transcription. For repressive modifications like 
H3K20me3 and H3K9me3, it was shown, that their levels 
are elevated in breast cancer cells (Leszinski et al. 2012). 
Another modification with repressive effect on gene tran-
scription, H3K27me3, Healy et al. could show that it was 
associated to low grading and inversely to Her-2-neu status 
(Healey et al. 2014). These results fit to our observance that 
activating modifications have a positive correlation to the 
Her2neu status.
In the present study, we showed that H3K4 tri-methyl-
ation and H3K4 acetylation are negative prognosticators 
for breast cancer patients. Even though the mechanisms 
of histone modifications are not fully understood, several 
Fig. 4  Correlation of H3K9ac and Ki67 and prognosis
Fig. 5  Role of H3K4me3 and H3K9ac for survival. a nuclear H3K4me3 expression and overall survival. b nuclear H3K4me3-expression and 
breast-cancer-specific survival. c H3K9ac expression and breast-cancer-specific survival
Histone modifications have been of great scientific inter-
est in the past years. After synthesis of histones, posttrans-
lational modifications like methylation or acetylation are 
performed. These can take place in the nucleus or in the 
cytoplasm (Annunziato and Hansen 2000; Wu et al. 2012). 
Posttranslational alterations, which can mainly be found at 
the loose N-termini, but also within the global domain of 
histones, have been shown to regulate the structure, acces-
sibility and replication of DNA and play an important role 
in fundamental cellular mechanisms in the cell cycle (Zhang 
et al. 2016). Aberrant histone modifications have been linked 
to the pathogenesis of several diseases, including inflamma-
tory diseases and cancer, as they cause a shift in the gene 
expression and the overall metabolic state of the cell (Shan-
mugam et al. 2018).
Previous studies have concentrated on the impact of spe-
cific histone modifications on the cell: it has been shown that 
while histone acetylation is mainly associated with gene acti-
vation, methylation can be associated with either repression 
or activation, depending on its position and level (mono/di/
2025Journal of Cancer Research and Clinical Oncology (2020) 146:2017–2027 
1 3
epigenetic therapies have shown great results in cancer treat-
ment. One promising substance class are HDAC inhibitors, 
which prevent histone deacetylases from detaching the acetyl 
group from a histone, inducing cell cycle arrest, differentia-
tion and cell death (Eckschlager et al. 2017). The HDAC 
inhibitors Vorinostat, Romidepsin and Belinostat have been 
approved by the FDA for the treatment of T cell lymphoma 
(Zhang et al. 2019). Many studies have concentrated on the 
combination of epigenetic therapy with well-established 
therapies and have demonstrated synergistic effects (Cao 
et al. 2015; Gao et al. 2016; Mann et al. 2007; Marks and 
Breslow 2007; Rettig et al. 2015). The addition of Vorinostat 
to Tamoxifen in breast cancer treatment resulted in tumor 
regression or prolonged disease stabilization in patients who 
had progressed on prior hormonal therapy (Thomas et al. 
2011). In preclinical trials, HDAC inhibitors showed the 
ability to re-sensitize tamoxifen-resistant cells and prevent 
hormone therapy resistance (Munster et al. 2011), as well as 
a potentiation of the immune checkpoint inhibitor blockade 
in triple negative breast cancer in mice (Terranova-Barberio 
et al. 2017).
Our results show significant correlations of H3K9ac, 
H3K4me3 to Her2neu and ER as well as to survival data in 
breast cancer. As we examined the level of histone modifica-
tions at a fixed time by immunohistochemistry, we cannot 
say, if these results are cause or consequence of the cancer 
phenotype. Further experiments are, therefore, needed.
Further investigation of histone modifications in breast 
cancer could lead to a deeper understanding of the molecular 
mechanisms of cancer development. It could result in reli-
able screening methods, as well as the identification of new 
therapeutic targets for breast cancer treatment.
Conclusions
Histone modifications play an important role in the prog-
nosis of breast cancer. H3K4me3 expression was correlated 
with positive estrogen receptor status, while H3K9ac stain-
ing was correlated with positive Her2 receptor status. High 
H3K4me3 and H3K9ac expression were correlated with 
shorter breast cancer-specific survival as well as shorter 
progression-free survival. Overall survival was decreased 
in patients with high nuclear H3K4me3 staining.
Several epigenetic therapies have already shown great 
results in cancer treatment. Further investigation of histone 
modifications in breast cancer could lead to a deeper under-
standing of the molecular mechanisms of cancer develop-
ment. It could result in the identification of new therapeutic 
targets for breast cancer treatment.
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